Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
4.0300+0.0700 (+1.77%)
As of 10:20AM EDT. Market open.

Eupraxia Pharmaceuticals Inc.

2067 Cadboro Bay Road
Suite 201
Victoria, BC V8R 5G4
Canada
250-590-3968
https://www.eupraxiapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees29

Key executives

NameTitlePayExercisedYear born
Dr. James A. Helliwell FRCPC, M.D.CEO & Director627.5kN/A1974
Mr. Bruce G. Cousins C.A., CPAPresident & CFO421.67kN/A1961
Dr. Amanda Malone Ph.D.Chief Scientific Officer465kN/A1981
Mr. Paul Anthony Brennan B.Sc., M.Sc.Chief Business Officer335kN/AN/A
Dr. Mark M. Kowalski M.D., Ph.D.Chief Medical OfficerN/AN/A1955
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Corporate governance

Eupraxia Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.